Login   |   Register
Cover Image


Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen

Christopher H. Bailey, Patrick J. Donovan, Glen J. Weiss

Authors information
  • Christopher H. Bailey
    Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Patrick J. Donovan
    Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Glen J. Weiss
    Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States. gweiss@tgen.org

Abstract


At the age of 83, a woman presented with an extremely rare cancer, basal cell adenocarcinoma (BCAC) of the supraglottic larynx. Pathology revealed a stage IVA tumor, pathological stage T4N0M0. She was treated with surgery and did not receive any adjuvant chemotherapy or radiation therapy. At the age of 93, during a routine examination, the patient was found to have palpable adenopathy and underwent a fine needle aspiration in June 2010. Pathology revealed similar histologic characteristics of her 2001 BCAC diagnosis, and further IHC stains revealed positive estrogen receptor staining.

Keywords


Basal cell adenocarcinoma; estrogen receptor; tamoxifen; supraglottic larynx

Full Text





Submitted: 2011-01-27 02:46:12
Published: 2011-12-13 14:49:53
Search for citations in Google Scholar
Related articles: Google Scholar

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


 

FOOTER

Rare Tumors [ISSN 2036-3605, eISSN 2036-3613] is an Open Access, peer-reviewed journal published by PAGEPress, Pavia, Italy. All credits and honors to PKP for their OJS.

 

 

 

 
 
© PAGEPress 2008-2014     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185